The profiling, identification, quantification and analysis of differentially expressed genes (DEGs) in response to drug treatment in lung cancer.
A549 cells
Differential gene expression (DEG)
Drug treatment
Ingenuity Pathway Analysis (IPA)
Lopinavir/ritonavir (LPV/r)
MRC-5 cells
Journal
MethodsX
ISSN: 2215-0161
Titre abrégé: MethodsX
Pays: Netherlands
ID NLM: 101639829
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
10
2020
accepted:
02
05
2021
entrez:
25
8
2021
pubmed:
26
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
The profiling and identification of genes that are differentially expressed is frequently used to underpin the underlying molecular mechanisms of biological conditions and provides a molecular foothold on biological questions of interest. However, this can be a daunting task since there is a cross talk and overlap of some of the components of the signalling pathways. The deregulation of the cell cycle signalling pathway is a hallmark of cancer, including lung cancer. Proper regulation of the cell cycle results in cellular homeostasis between cell proliferation and cell death. The comprehension of the cell cycle regulation in drug metabolism studies is of significance. This study aimed at elucidating the regulation of cell cycle genes' in response to LPV/r in lung cells. Thus, this study describes methodology for revealing molecular mechanisms employed by LPV/r to induce stress on genomic DNA. This approach is based on the interrogation of a panel of 84 genes related to the cell cycle pathway, and how the differentially expressed genes' expression pattern corroborates loss in nuclear integrity (phenotypic observation). MAD2L2, AURKB and CASP3 gene expressions were further confirmed by RT-qPCR. Furthermore, the use of
Identifiants
pubmed: 34430277
doi: 10.1016/j.mex.2021.101381
pii: S2215-0161(21)00174-6
pmc: PMC8374453
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101381Informations de copyright
© 2021 The Author(s). Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Clin Microbiol. 2003 Aug;41(8):3922-5
pubmed: 12904419
Cold Spring Harb Protoc. 2011 Jan 01;2011(1):pdb.prot5556
pubmed: 21205856
Stud Hist Philos Sci. 2016 Apr;56:113-21
pubmed: 27083091
Anal Biochem. 2014 Oct 15;463:38-44
pubmed: 24983903
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Cancer Biol Med. 2017 Nov;14(4):348-362
pubmed: 29372101
PLoS One. 2015 Jun 18;10(6):e0130277
pubmed: 26086472
J Exp Clin Cancer Res. 2016 Sep 27;35(1):153
pubmed: 27670139
Oncotarget. 2017 Apr 4;8(14):23937-23954
pubmed: 28147341
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
S Afr Med J. 2016 Jun 17;106(7):666-8
pubmed: 27384354
J Mater Sci Mater Med. 2011 Jan;22(1):63-9
pubmed: 21052793
Pan Afr Med J. 2020 Feb 12;35:38
pubmed: 32499854
Int J Mol Sci. 2018 Jun 06;19(6):
pubmed: 29882812
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Int J Cancer. 2017 Apr 15;140(8):1713-1726
pubmed: 27870005
Clin Cancer Res. 2007 Sep 1;13(17):5183-94
pubmed: 17785575
Anticancer Res. 2019 Jul;39(7):3757-3765
pubmed: 31262902